The ability to successfully replace lost nigral dopaminergic neurons in Parkinson's disease
(PD) has been clearly shown with fetal ventral mesencephalic transplants, albeit …

Early clinical trials designed to treat Parkinson's disease by transplantation of fetal tissue
containing dopamine neuron precursors yielded promising results, but the approach retains …

Parkinson disease (PD) is characterized by loss of the A9 nigral neurons that provide
dopaminergic innervation to the striatum. This discovery led to the successful instigation of …

Treating neurodegenerative diseases with cell transplantation has been within reach since
the first pioneering clinical trials in which dopamine neuron progenitors from the fetal brain …

✓ In this review, the authors discuss recent advances in the field of cell therapy for Parkinson
disease (PD). They compare and contrast recent clinical trials using fetal dopaminergic …

Motor dysfunctions in Parkinson's disease are considered to be primarily due to the
degeneration of dopaminergic neurons in the substantia nigra pars compacta …

Over the past three decades, significant progress has been made in the development of
potential regenerative cell-based therapies for neurodegenerative disease, with most …

Stem cell replacement has emerged as the novel therapeutic strategy for Parkinson's
disease (PD). Control of motor behavior is lost in PD due to the selective degeneration of …

The clinical trials with intrastriatal transplantation of human fetal mesencephalic tissue, rich
in dopaminergic neurons, in Parkinson's disease (PD) patients show that cell replacement …

The aim of stem cell therapy for Parkinson's disease is to reconstruct nigro–striatal neuronal
pathways using endogenous neural stem/precursor cells or grafted dopaminergic neurons …